Guidelines for Use
The guideline named YONSA (abiraterone, submicronized) requires that the patient have a diagnosis of metastatic castration-resistant prostate cancer (CRPC). In addition, the requested medication must be used combination with methylprenisolone.
Rationale
Promote appropriate utilization of Yonsa based on FDA approved indication and dosing.
Indications for Use
Yonsa is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).
Dosage and Administration
The recommended dose of Yonsa is 500 mg (four 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily.
Patients receiving Yonsa should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
References
Yonsa [Prescribing Information]. Sun Pharma. Cranbury, NJ. May 2018.